NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Therapeutic Education in Parkinson's Disease: What Impact on Drug Representations of Patients? (ETPARK-REMED)

CompletedNA

Sponsor: University Hospital, Toulouse

Conditions: Parkinson Disease

Interventions: Therapeutic education workshop, Speaking Therapy

Countries: France

Dopaminergic drug can have adverse effects leading to potential serious consequences. Therapeutic patient education must promote the understanding of drugs to improve its management. This study tries to evaluate the effect of therapeutic education workshop on Parkinson disease's drug (drug workshop) on the evolution of drug's representations in patients with Parkinson's disease compared to a control group.

Eligibility overview

Sex: ALL

Age: 18 Years to 75 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Patients with Parkinson's disease according to the United Kingdom Parkinson Disease Society Brain Bank (UKPDSBB) criteria,
* Patients who are already in therapeutic education program ETPARK,
* Patients who need and want to participate in therapeutic education workshop on Parkinson disease drug,
* Patients with health insurance,
* Patients who have signed a written informed consent form.

Exclusion Criteria:

* Patients suffering from another parkinsonian syndrome (multiple system atrophy, progressive supranuclear palsy etc.),
* Patients who has already done workshop on Parkinson disease drug (program ETPARK)
* Patients already included in clinical trial during the study,
* Patients who have severe psychiatric disorders or dopaminergic psychosis,
* Patients with cognitive impairment,
* Patients unable to complete the various scales used in the study,
* Patients under juridical protection,
* Women pregnant or breastfeeding.

Locations (1)

Toulouse, Occitanie, France